Simba Gill, CEO of Evelo Biosciences

While down 87% YOY, Evelo gets Flag­ship and oth­ers to in­fuse new cap­i­tal for come­back hope

Just four years af­ter Flag­ship spin­out Evelo Bio­sciences went pub­lic in an IPO worth $85 mil­lion, the biotech has seen its share price tank from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.